SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05375084 |
|
Recruitment Status :
Recruiting
First Posted : May 16, 2022
Last Update Posted : February 16, 2024
|
Sponsor:
Navire Pharma Inc., a BridgeBio company
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Navire Pharma Inc., a BridgeBio company
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | July 2024 |
| Estimated Study Completion Date : | January 2025 |